Fred E. Cohen - Feb 12, 2024 Form 4 Insider Report for Kyverna Therapeutics, Inc. (KYTX)

Role: Director, 10%+ Owner
Signature: By: /s/ Fred E. Cohen
Stock symbol: KYTX
Transactions as of: Feb 12, 2024
Transactions value $: $0
Form type: 4
Date filed: 2/14/2024, 07:03 PM
Previous filing: Feb 7, 2024
Next filing: May 28, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	KYTX	Common Stock	Conversion of derivative security		+4.52M			4.52M	Feb 12, 2024	See Footnote	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	KYTX	Series A-1 Redeemable Convertible Preferred Stock	Conversion of derivative security	$0	-4.4M	-100%	$0.00^*	0	Feb 12, 2024	Common Stock	967K		See Footnote	F2, F3
transaction	KYTX	Series A-2 Redeemable Convertible Preferred Stock	Conversion of derivative security	$0	-8.83M	-100%	$0.00^*	0	Feb 12, 2024	Common Stock	1.94M		See Footnote	F2, F3
transaction	KYTX	Series B Redeemable Convertible Preferred Stock	Conversion of derivative security	$0	-7.36M	-100%	$0.00^*	0	Feb 12, 2024	Common Stock	1.62M		See Footnote	F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents shares of the Issuer's Common Stock received upon conversion of shares of the reported series of preferred stock on a 1-for-4.5511 basis without payment of further consideration.
F2	Shares held directly by Vida Ventures, LLC ("Vida"). Vida Ventures Advisors, LLC is the investment advisor to Vida. Dr. Arie Belldegrun, Leonard Potter and the Reporting Person are the managing members of Vida Ventures Advisors, LLC, and may be deemed to share voting and dispositive power over the shares held by Vida, but each disclaims beneficial ownership of the shares held by Vida except to the extent of such person's pecuniary interest therein, if any.
F3	The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering.